ES2721849T3 - Forma oral sólida dotada de un doble perfil de liberación que comprende multipartículas - Google Patents

Forma oral sólida dotada de un doble perfil de liberación que comprende multipartículas Download PDF

Info

Publication number
ES2721849T3
ES2721849T3 ES09745961T ES09745961T ES2721849T3 ES 2721849 T3 ES2721849 T3 ES 2721849T3 ES 09745961 T ES09745961 T ES 09745961T ES 09745961 T ES09745961 T ES 09745961T ES 2721849 T3 ES2721849 T3 ES 2721849T3
Authority
ES
Spain
Prior art keywords
hours
release
active principle
cellulose acetate
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09745961T
Other languages
English (en)
Spanish (es)
Inventor
Florence Guimberteau
Anne-Sophie Daviaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Ireland Ltd
Original Assignee
Flamel Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Ireland Ltd filed Critical Flamel Ireland Ltd
Application granted granted Critical
Publication of ES2721849T3 publication Critical patent/ES2721849T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
ES09745961T 2008-04-18 2009-04-17 Forma oral sólida dotada de un doble perfil de liberación que comprende multipartículas Active ES2721849T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7125008P 2008-04-18 2008-04-18
FR0852627A FR2930147B1 (fr) 2008-04-18 2008-04-18 Forme orale solide dotee d'un double profil de liberation
PCT/FR2009/050719 WO2009138642A1 (fr) 2008-04-18 2009-04-17 Forme orale solide dotee d'un double profil de liberation comprenant des multiparticules

Publications (1)

Publication Number Publication Date
ES2721849T3 true ES2721849T3 (es) 2019-08-05

Family

ID=40110982

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09745961T Active ES2721849T3 (es) 2008-04-18 2009-04-17 Forma oral sólida dotada de un doble perfil de liberación que comprende multipartículas

Country Status (14)

Country Link
US (1) US20090291137A1 (https=)
EP (1) EP2276474B1 (https=)
JP (1) JP5687185B2 (https=)
KR (1) KR101380507B1 (https=)
CN (1) CN102046155A (https=)
AU (1) AU2009247921B2 (https=)
BR (1) BRPI0910572B1 (https=)
CA (1) CA2721232C (https=)
ES (1) ES2721849T3 (https=)
FR (1) FR2930147B1 (https=)
IL (1) IL208572A (https=)
MX (1) MX339671B (https=)
WO (1) WO2009138642A1 (https=)
ZA (1) ZA201007238B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
US11957792B2 (en) 2012-04-19 2024-04-16 Glatt Ag Taste-masked pharmaceutical compositions containing diclofenac
EP3201259A1 (en) * 2014-09-30 2017-08-09 Dow Global Technologies Llc Aqueous ethylcellulose dispersions with polymeric additive
JP2018504454A (ja) * 2015-01-12 2018-02-15 ナノ ファーマシューティカル ラボラトリーズ エルエルシーＮａｎｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｌａｂｏｒａｔｏｒｉｅｓ ＬＬＣ 積層徐放型マイクロビーズ及びその作製方法
JP6112696B1 (ja) * 2015-10-05 2017-04-12 富山化学工業株式会社 ソリスロマイシンを含む錠剤
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
FR3089406B1 (fr) 2018-12-07 2020-11-20 Urgo Rech Innovation Et Developpement Dispositif de retenue et système de contention comprenant un article de contention et un tel dispositif de retenue
FR3089405A1 (fr) 2018-12-07 2020-06-12 Urgo Recherche Innovation Et Developpement Dispositif de retenue et système de contention comprenant un article de contention et un tel dispositif de retenue
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
EP0653935B1 (en) * 1992-08-05 2002-05-08 F.H. FAULDING & CO. LIMITED Pelletised pharmaceutical composition
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5458888A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
EP1258241A1 (en) * 2001-05-16 2002-11-20 BIOPROGRESS S.p.A. Method of increasing the bioavailability of nimesulide
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US7294347B2 (en) * 2004-06-21 2007-11-13 Council Of Scientific And Industrial Research Coating compositions for bitterness inhibition
US20060263429A1 (en) * 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
GB0517205D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20080069878A1 (en) * 2006-08-31 2008-03-20 Gopi Venkatesh Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs

Also Published As

Publication number Publication date
WO2009138642A1 (fr) 2009-11-19
IL208572A0 (en) 2010-12-30
KR20110005876A (ko) 2011-01-19
US20090291137A1 (en) 2009-11-26
BRPI0910572B1 (pt) 2021-10-13
JP5687185B2 (ja) 2015-03-18
MX339671B (es) 2016-06-03
CA2721232C (fr) 2016-03-29
CN102046155A (zh) 2011-05-04
FR2930147B1 (fr) 2013-02-08
FR2930147A1 (fr) 2009-10-23
MX2010011409A (es) 2010-12-02
CA2721232A1 (fr) 2009-11-19
EP2276474B1 (fr) 2019-03-06
ZA201007238B (en) 2011-06-29
EP2276474A1 (fr) 2011-01-26
KR101380507B1 (ko) 2014-04-11
IL208572A (en) 2016-02-29
JP2011518139A (ja) 2011-06-23
BRPI0910572A2 (https=) 2017-08-08
AU2009247921A1 (en) 2009-11-19
AU2009247921B2 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
ES2721849T3 (es) Forma oral sólida dotada de un doble perfil de liberación que comprende multipartículas
ES2655622T3 (es) Una formulación de fármaco de liberación retardada
ES2526092T3 (es) Formulaciones de olanzapina en nanopartículas inyectables
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
JP2019507797A5 (https=)
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
WO2013016697A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
ES2569354T3 (es) Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica
CL2013003331A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz.
BR0107874A (pt) Implante farmacêutico para controlavelmente liberar uma droga, método para controlavelmente liberar uma droga em um indivìduo, e, método para preparar o implante
HRP20241127T1 (hr) Formulacije i doze pegilirane urikaze
FI3154594T3 (fi) Fap-aktivoituja terapeuttisia aineita ja niihin liittyviä käyttöjä
PE20071139A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
MX350501B (es) Nanotecnologia de vacuna.
JP2014528431A5 (https=)
WO2016210003A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
RU2015128609A (ru) Перенасыщенные стабилизированные наночастицы для слаборастворимых лекарственных средств
RU2014127884A (ru) Способы лечения сердечно-сосудистого нарушения
DOP2015000028A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
AR076305A1 (es) Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo
PE20110876A1 (es) Formulacion de deposito de octreotida con niveles de exposicion constantemente altos
BR112013002280A2 (pt) composições farmacêuticas orais de liberação controlada compreendendo blonanseina
JP2015512420A5 (https=)